1 3-Bisurea Colchicum Autumnale Bulb Ferrosoferric
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- 1 3-Bisurea Colchicum Autumnale Bulb Ferrosoferric
- 1,3-Bisurea / Colchicum / Nux-Vomica Compound: Insufficient Data for Repurposing Evaluation
1,3-Bisurea / Colchicum / Nux-Vomica Compound: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This submission contains a multi-component mixture of nine substances (including Colchicum autumnale bulb, Lithium carbonate, Strychnos nux-vomica seed, and Uric acid) that resembles a homeopathic or traditional compound preparation. No approved original indication, no TxGNN predicted indications, and no market authorisation were identified for this formulation as a combined entity; consequently, no repurposing assessment can be completed at this stage, and the recommendation is a full Hold pending data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory approval found) |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only (no candidates generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No repurposing prediction was generated by TxGNN for this compound mixture, so a standard mechanistic rationale cannot be provided. The following is a descriptive note on the constituent substances based on publicly known pharmacology.
The nine components span very different pharmacological classes: Colchicum autumnale is the botanical source of colchicine (an anti-inflammatory mitotic inhibitor used in gout); Strychnos nux-vomica contains strychnine and brucine (historically used as tonics, now recognised as highly toxic alkaloids); Lithium carbonate is a mood-stabilising agent used in bipolar disorder; and Uric acid is an endogenous metabolite implicated in gout pathophysiology. The remaining components (1,3-Bisurea, Ferrosoferric phosphate, Glutamine, Sodium carbonate, Toxicodendron pubescens leaf) add further chemical heterogeneity.
This combination profile is consistent with a homeopathic or complex traditional medicine preparation rather than a single-molecule drug. Because TxGNN’s knowledge graph operates on individual drug–disease pairs mapped through DrugBank IDs, a compound with no DrugBank entry and no unified INN cannot be scored against the disease ontology, which explains the absence of any predicted indication.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-component formulation.
Literature Evidence
Currently no related literature available for this specific formulation as a combined entity.
US Market Information
No US market authorisations found for this formulation.
Safety Considerations
Please refer to the package insert for safety information.
Note for reviewers: Several individual components carry significant safety concerns that should be evaluated before any further development:
- Strychnos nux-vomica (strychnine/brucine): narrow therapeutic index; potential for CNS toxicity and convulsions at sub-therapeutic margins.
- Colchicum autumnale (colchicine): dose-dependent toxicity; severe interactions with P-gp and CYP3A4 inhibitors.
- Toxicodendron pubescens (poison oak, urushiol-containing): contact sensitiser; systemic exposure data limited.
- Lithium carbonate: narrow therapeutic index; renal and thyroid monitoring required; multiple drug interactions.
These concerns were not captured in the Evidence Pack due to Blocking data gap DG001 (TFDA warnings/contraindications not retrieved) and High-severity gap DG002 (MOA not retrieved).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline produced zero predicted indications for this submission because the compound mixture has no DrugBank ID and no recognised unified INN, making knowledge-graph traversal impossible. Before any repurposing analysis can proceed, the formulation must be disambiguated and its regulatory status established.
To proceed, the following is needed:
- Formulation clarification: Determine whether this is a registered homeopathic product or an investigational fixed-dose combination; if homeopathic, identify the regulatory authority under which it is (or was) filed.
- Individual component mapping: Assign DrugBank IDs to each active constituent and re-run TxGNN independently for each component; results can then be aggregated at the formulation level.
- DG001 remediation (Blocking): Retrieve official TFDA or equivalent package-insert warnings and contraindications for each constituent to enable safety pre-screening.
- DG002 remediation (High): Obtain confirmed MOA data for each constituent from DrugBank or peer-reviewed sources.
- Original indication documentation: Establish the approved or intended therapeutic indication(s) for the combined preparation before a “from X to Y” repurposing trajectory can be defined.
- Toxicity risk assessment: Given the presence of strychnine-containing and urushiol-containing botanicals, a formal cytotoxicity and genotoxicity pre-screen is strongly recommended prior to any clinical repurposing proposal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.